Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

Inclusion Criteria: * The investigator must assess the capacity of the subject to provide informed consent prior to enrollment and throughout the trial. * Male and female subjects who completed both the 12-week double-blind treatment period and the 30-day safety follow-up visit of the previous brexpiprazole trial. * Subject has an identified caregiver who is usually assigned to care for the subject on a regular basis, has sufficient contact to describe the subject's symptoms, and has direct observation of the subject's behavior. * Subject is able to comply with the protocol requirements. Exclusion Criterion: * Subjects who, in the opinion of the investigator, medical monitor, or sponsor should not participate in the trial.